Newer antidepressants for the treatment of depression in adults

BMJ (Online)

Volumn 344, Issue 7841, 2012, Pages

  Hatcher, Simon ^a   Arroll, Bruce ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LOFEPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLOXATONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIMELDINE;

ANXIETY DISORDER; BIPOLAR DISORDER; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; HEALTH ASSESSMENT QUESTIONNAIRE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; LONG TERM CARE; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SHORT SURVEY; SIDE EFFECT; SUICIDE; SWEATING; TREATMENT INDICATION; TREATMENT RESPONSE; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA; ARTICLE; COST BENEFIT ANALYSIS; DRUG SUBSTITUTION; ECONOMICS; FEMALE; MALE; META ANALYSIS (TOPIC); METHODOLOGY; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DRUG SUBSTITUTION; FEMALE; GREAT BRITAIN; HUMANS; MALE; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84857467710     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d8300     Document Type: Short Survey

References (35)

1. NHS Information Centre for Health and Social Care. www.ic.nhs.uk/ services/prescribing-support-unit-psu/using-the-service/reports-publications- and-presentations/reports/national-prescribing-costs-and-items
2. Nutt D. Beyond psychoanaleptics - can we improve antidepressant drug nomenclature? J Psychopharmacol 2009;23:343-45.
3. National Institute for Health and Clinical Excellence. The treatment and management of depression in adults (update). (Clinical guideline 90.) 2009. http://guidance.nice.org.uk/CG90.
4. Hetrick SE, McKenzie JE, Merry SN. The use of SSRIs in childhood and adolescents. Curr Opin Psychiatry 2010;23(1):53-7.
5. Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010;340:c1468.
6. Moore M, Yuen HM, Dunn N, Mulee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using general practice research database. BMJ 2009;339:b3999.
7. Pagura J, Katz LY, Mojtabai R, Druss BG, Cox B, Sareen J. Antidepressant use in the absence of common mental disorders in the general population. J Clin Psychiatry 2011;72:494-501.
8. Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003;327:1144-6. (Pubitemid 37421811)
9. Nease DE, Malouin JM. Depression screening: a practical strategy. J Fam Pract 2003;52:118-26. (Pubitemid 36188089)
10. Arroll B, Goodyear-Smith F, Kerse N, Hwang M, Crengle S, Gunn J, et al. The prevalence of depression among Maori patients in Auckland general practice. J Primary Health Care 2009;1(1):26-9.
11. Macarthur Foundation. 2009. www.depression-primarycare.org.
12. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosomatic Research 2002;52(2):69-77. (Pubitemid 34192886)
13. Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006;166:2314-21. (Pubitemid 44833355)
14. Wu P, Fuller C, Liu X, Lee H-C, Fan B, Hoven CW, et al. Use of complementary and alternative medicine among women with depression: results of a national survey. Psychiatric Services 2007;58:349-56. (Pubitemid 46480051)
15. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5(2):e45.
16. Horder J, Matthews P, Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 2010; http://jop.sagepub.com/ content/25/10/1277
17. Fountoulakis KN, Moller H-J. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011;14:405-12.
18. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
19. Cameron IM, Cardy A, Crawford JR, du Toit SW, Hay S, Lawton K, et al. Measuring depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D and BDI-II. Br J Gen Pract 2011;61(588):e419-26.
20. Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
21. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, van Noord M, et al. Comparative benefits and harms of second generation antidepressants for treating major depressive disorder. Ann Intern Med 2011;155:772-85.
22. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.
23. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Safety 2008;31:851-65.
24. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(suppl 1):S26-43.
25. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
26. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric populations: The burden of side effects and interactions and their impact on adherence and costs. Am J Geriatric Psychiatry 2011;19:211-21.
27. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1-9.
28. National Institute for Health and Clinical Excellence. Antenatal and postnatal mental health: clinical management and service guidance (Clinical guideline 45.) 2007. http://guidance.nice.org.uk/CG45.
29. Depression, antidepressants and heart disease. Drug Ther Bull 2008;46(4):29-32.
30. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010;71:1565-75.
31. Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 2009;13(22).
32. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009;3:CD007954.
33. Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8.
34. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibtor antidepressant action: systematic review and meta analysis. Arch Gen Psychiatry 2006;63:1217-23. (Pubitemid 44708080)
35. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71(1):43-64.